INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue242,275330,323219,092
Cost of Revenue25,39328,85422,578
Gross Profit216,882301,469196,514
Operating Expenses
Research Development73,91356,78133,136
Selling General and Administrative131,743143,616102,388
Non Recurring3,90010,61610,616
Total Operating Expenses---
Operating Income or Loss7,32690,45660,990
Income from Continuing Operations
Total Other Income/Expenses Net1,098538153
Earnings Before Interest and Taxes8,42490,99461,143
Interest Expense---
Income Before Tax8,42490,99461,143
Income Tax Expense83432,94125,089
Minority Interest---
Net Income From Continuing Ops7,59058,05336,054
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income7,59058,05336,054
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares7,59058,05336,054